164 related articles for article (PubMed ID: 21817902)
21. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
Li HT; Lu YY; An YX; Wang X; Zhao QC
Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
[TBL] [Abstract][Full Text] [Related]
22. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.
Shigaki H; Baba Y; Watanabe M; Miyake K; Murata A; Iwagami S; Ishimoto T; Iwatsuki M; Yoshida N; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S485-91. PubMed ID: 23274581
[TBL] [Abstract][Full Text] [Related]
23. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.
Lamy A; Blanchard F; Le Pessot F; Sesboüé R; Di Fiore F; Bossut J; Fiant E; Frébourg T; Sabourin JC
Mod Pathol; 2011 Aug; 24(8):1090-100. PubMed ID: 21516079
[TBL] [Abstract][Full Text] [Related]
24. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
25. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
[TBL] [Abstract][Full Text] [Related]
26. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
27. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
[TBL] [Abstract][Full Text] [Related]
28. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
[TBL] [Abstract][Full Text] [Related]
29. Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers.
Packham D; Ward RL; Ap Lin V; Hawkins NJ; Hitchins MP
Diagn Mol Pathol; 2009 Jun; 18(2):62-71. PubMed ID: 19430299
[TBL] [Abstract][Full Text] [Related]
30. BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours.
Serrano C; Simonetti S; Hernández-Losa J; Valverde C; Carrato C; Bagué S; Orellana R; Somoza R; Moliné T; Carles J; Huguet P; Romagosa C; Ramón y Cajal S
Histopathology; 2013 Feb; 62(3):499-504. PubMed ID: 23190154
[TBL] [Abstract][Full Text] [Related]
31. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
32. Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients.
Seekhuntod S; Thavarungkul P; Chaichanawongsaroj N
PLoS One; 2016; 11(1):e0147672. PubMed ID: 26812617
[TBL] [Abstract][Full Text] [Related]
33. The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population.
Ozen F; Ozdemir S; Zemheri E; Hacimuto G; Silan F; Ozdemir O
Genet Test Mol Biomarkers; 2013 Feb; 17(2):135-9. PubMed ID: 23297805
[TBL] [Abstract][Full Text] [Related]
34. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
Carotenuto P; Roma C; Cozzolino S; Fenizia F; Rachiglio AM; Tatangelo F; Iannaccone A; Baron L; Botti G; Normanno N
Int J Oncol; 2012 Feb; 40(2):378-84. PubMed ID: 21971641
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of real-time PCR-optimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas].
Qiu T; Ling Y; Chen Z; Shan L; Guo L; Lü N; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):599-602. PubMed ID: 23157827
[TBL] [Abstract][Full Text] [Related]
36. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
37. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.
Karkouche R; Bachet JB; Sandrini J; Mitry E; Penna C; Côté JF; Blons H; Penault-Llorca F; Rougier P; Saint André JP; Emile JF
Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1430-7. PubMed ID: 23114745
[TBL] [Abstract][Full Text] [Related]
38. Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?
Koçer NE; Kayaselçuk F
Target Oncol; 2014 Jun; 9(2):171-5. PubMed ID: 23588415
[TBL] [Abstract][Full Text] [Related]
39. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
[TBL] [Abstract][Full Text] [Related]
40. Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.
Chang LC; Chiu HM; Shun CT; Liang JT; Lin JT; Chen CC; Lee YC; Wu MS
BMC Gastroenterol; 2014 Dec; 14():221. PubMed ID: 25551625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
